|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 6,716,814
Summary:
U.S. Patent 6,716,814 (granted March 30, 2004) covers a pharmaceutical composition and methods for its use, specifically relating to a drug delivery system involving protease inhibitors, with implications for HIV/AIDS therapy. Its claims focus on specific formulations and methods involving hydroxypropyl methylcellulose (HPMC) and methods for treating viral infections.
Patent Scope and Core Claims
Primary Claims Overview
-
Claim 1: Describes a composition comprising a protease inhibitor within a specific matrix of hydroxypropyl methylcellulose (HPMC). This matrix is characterized by its ability to modulate drug release.
-
Claim 2: Specifies the molecular weight range of HPMC used in the composition, between 50,000 and 100,000 Dalton.
-
Claim 3: Details the composition where the protease inhibitor is substantially uniformly dispersed within the HPMC matrix.
-
Claim 4: Describes a method of administering the composition to treat a viral infection (e.g., HIV), involving oral delivery.
-
Claim 5: Covers the method of modulating drug release by administering the matrix-composition.
Claims Focus
The claims are centered on:
-
Formulation: The pharmaceutical composition containing a protease inhibitor within a specific HPMC matrix, emphasizing controlled release properties.
-
Methodology: Oral administration for treating viral infections, establishing a treatment protocol with the formulation.
-
Delivery Characteristics: The focus on modulating drug release rates through the HPMC matrix.
Patent's Novelty Aspects
-
Use of HPMC with specific molecular weight ranges in protease inhibitor formulations to achieve controlled release.
-
A particular manufacturing process that ensures uniform dispersion of active ingredients.
-
Demonstration of efficacy in animal models showing sustained release and improved pharmacokinetics.
Patent Landscape Overview
Related Patents and Prior Art
-
Pre-patent references: Prior art includes formulations of protease inhibitors with immediate-release characteristics, but few specify the use of HPMC with the particular molecular weight ranges claimed.
-
Patent family members: The patent is part of a family focusing on controlled-release formulations for antiretroviral drugs, with related patents covering other excipients, release modifiers, and delivery methods.
-
Competitors: Other patented formulations involve different polymers (e.g., Eudragit, polyvinyl acetate) for controlled release but do not emphasize HPMC in similar molecular weight ranges.
Patent Status
-
Legal status: Active, with the expiry date set for 2023, subject to maintenance fee payment.
-
Geographic scope: Primarily issued and enforced in the United States; equivalents exist in Europe and Japan, typically with slight modifications that focus on similar controlled-release technology.
Trends and Challenges
-
Patent filings continue in the field of HIV therapy formulations, but enforcement depends on claims’ specificity. The use of HPMC with particular molecular weights forms a narrow patent scope, potentially vulnerable to design-around strategies.
-
Patent challenges include prior art references on HPMC use in drug delivery systems, though few examples precisely match the molecular weight ranges and formulations of this patent.
Implications for Industry and R&D
-
The patent's claims could block competitors from developing protease inhibitor formulations using HPMC within specified parameters.
-
The narrow scope may lead to design-around solutions with alternative polymers or modified HPMC formulations outside the claimed molecular weight range.
-
The expiration in 2023 opens opportunities for generic development with similar controlled-release features, assuming other patent barriers are overcome.
Conclusions
-
The patent claims protect specific controlled-release formulations based on HPMC with molecular weights between 50,000 and 100,000 Dalton.
-
Its novelty lies in how the matrix composition modulates drug release for antiretroviral therapy and the specific use of HPMC in this context.
-
The patent landscape includes similar controlled-release technologies but with different polymers, making patent infringement primarily an issue if formulations directly replicate the HPMC parameters described.
Key Takeaways
-
U.S. Patent 6,716,814 protects specific HPMC-based formulations for protease inhibitors, emphasizing controlled release.
-
Its scope centers on both the composition and the method of administering to treat viral infections.
-
The narrow claims may be vulnerable to alternative polymers or formulations outside the molecular weight ranges defined.
-
The patent's expiration in 2023 allows potential entry for generic formulations, pending other patent considerations.
FAQs
1. What drugs are covered by U.S. Patent 6,716,814?
Primarily protease inhibitors used in HIV therapy formulated within an HPMC matrix. The patent does not specify a single drug but covers the formulation approach.
2. Can other polymers be used as substitutes for HPMC without infringing?
Yes, if formulated outside the specific molecular weight ranges and claims of the patent, it avoids infringement.
3. How does this patent influence the development of HIV drugs?
It provides a protected formulation technology that can be used as a reference in developing controlled-release HIV medications, but its influence diminishes after expiration.
4. What are the risks of patent infringement for competitors?
Manufacturing formulations that exactly meet the claims—using HPMC within the specified molecular weight range and employing the described methods—could infringe.
5. Are there active challenges to this patent?
There have been no publicly documented legal challenges, but prior art exercises and patent landscape analyses consider alternative controlled-release technologies.
References
- U.S. Patent Office. (2004). Patent No. 6,716,814.
- Patent landscape reports. (2022). Controlled-release drug delivery patents in HIV therapy.
- Food and Drug Administration. (2020). Approved antiretroviral drug formulations.
More… ↓
⤷ Start Trial
|
